BenevolentAI
principles and bene of our technology approach industry challenges half of clinical failures due to poor understanding of disease biology mechanisms disease approach scientists can connect or infer shared mechanisms across diseases single modality data each with limitations and biases often limited understanding of what drives lab phenotypic effects much of target discovery is not a scalable or repeatable process approach biology comprehensive data approach hypothesis driven based benefits disease agnostic modality agnostic enables novel target accelerates discovery scalable repeatable potential to increase probability of success | BenevolentAI
Company
Deck Type
Deck date
September 2022
Slide
16 of 74
Similar slides by BenevolentAI
Investor Presentation
October 2022
Related slides by other companies
SPAC
November 2020
SPAC
November 2021
Other recent decks by BenevolentAI
Results
March 2024
Investor Conference
January 2024
Investor Presentation
May 2023
Results
March 2023
Search Thousands of Presentations by World Leading Companies

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases
© 2021-2023 Slidebook.io